TherOx gets FDA panel date
This article was originally published in The Gray Sheet
Executive SummaryFDA's Circulatory System Devices Panel will meet March 18 in Gaithersburg, Md., to vote on a pre-market approval application for the firm's Aqueous Oxygen System for acute myocardial infarction patients who have undergone successful revascularization up to six hours after symptom onset. The system is used to hyperoxygenate and reinfuse a patient's blood at the infarction site
You may also be interested in...
Scrip’s on-the-ground team in Asia talks about how the regional and wider pharma industry and policymakers have responded so far to the spreading coronavirus outbreak, with a focus on the expedited development of potential drugs and vaccines.
Oncologic Drugs Advisory Committee votes 6-5 that ramucirumab’s benefit/risk profile is favorable in first-line lung cancer, but 13-2 that pivotal trial data do not support approval of Steba’s vascular-targeted, photodynamic therapy for low-risk prostate cancer.